External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Rheumatology

Rheumatology

Disease
Giant Cell Arteritis Rheumatoid Arthritis Lupus Nephritis Juvenile Arthritis

Preview the latest medical materials

  • Rheumatology

Sign up or login to unlock the full suite of MEDICALLY features
Nov 13 / Roche and Genentech
Long-term Efficacy and Safety of Subcutaneous Tocilizumab in Patients With Polyarticular or Systemic Juvenile Idiopathic Arthritis – an Extension Study of 2 Phase 1b Clinical Trials
Oral presentation slides for ACR 2022.
Rheumatology Juvenile arthritis ACR-2022

Sign up or login to unlock the full suite of MEDICALLY features
Jun 1 / Roche
Outcomes During and After Long-Term Tocilizumab Treatment in Patients with Giant Cell Arteritis
In this retrospective analysis conducted using electronic medical records from patients with GCA who received tocilizumab for ≥9 months at a single center, time to relapse and annualized relapse rate during and after tocilizumab treatment, prednisone use and safety were assessed.
Rheumatology Giant Cell Arteritis EULAR-2022

Sign up or login to unlock the full suite of MEDICALLY features
Jun 1 / Roche
Intravenous Tocilizumab for the Treatment of Giant Cell Arteritis: A Phase Ib Dose-Ranging Pharmacokinetic Bridging Study
This Phase Ib study (NCT03923738) investigated the pharmacokinetics (PK), pharmacodynamics (PD), safety and exploratory efficacy of 2 dose levels of intravenous tocilizumab in patients with GCA.
Rheumatology Giant Cell Arteritis EULAR-2022
View more assets
Upcoming Congresses
Access to Roche and Genentech's latest medical information
View related congresses

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.